ENETS 2021 VIRTUAL

18th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease

25 – 27 February 2021

PRELIMINARY SCIENTIFIC PROGRAMME

Time Zone: Central European Time (CET)
## Thursday, 25.02.2021

### Welcome
**Time:** Thursday 10:45 - 11:00  
**Speaker:** Marianne Ellen Pavel, GER

### Plenary lecture
**Time:** Thursday 11:00 - 11:30  
**Moderator:** Marianne Ellen Pavel, GER

11:00 - 11:30  **Immunotherapy in cancer - How to apply immunotherapy in NET**  
*Wolf Hervé Fridman, FRA*

### Pathology of neuroendocrine neoplasms
**Time:** Thursday 11:30 - 12:45  
**Moderator:** Anne Couvelard, FRA / Marianne Ellen Pavel, GER

11:30 - 11:45  **New subcategories of NENs: Update on WHO and markers**  
*Massimo Milione, ITA*

11:45 - 12:00  **Spatial and temporal heterogeneity in NET: A clue to understand (naïve and chemoinduced) tumor progression?**  
*Jerome Cros, FRA*

12:00 - 12:15  **Is the molecular transition from NET to NEC-like clinically relevant?**  
*Halfdan Sorbye, NOR*

12:15 - 12:30  **Clinical case discussion**  
*Jerome Cros, FRA / Halfdan Sorbye, NOR*

12:30 - 12:45  **Discussion**

### BREAK
**Time:** Thursday 12:45 - 13:30

### Best abstracts: Clinical science
**Time:** Thursday 13:30 - 14:45  
**Moderator:** Eva Tiensuu Janson, SWE / Thomas Walter, FRA

13:30 - 13:40  **Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors. An international double-blind, placebo-controlled randomized phase II. Prodigie 31 REMINET. A FFCD study**

13:40 - 13:45  **Q & A**

13:45 - 13:53  **Management of early stage lung carcinoid: Analysis of NCDB database**

13:53 - 13:57  **Q & A**

13:57 - 14:05  **Automatized hepatic tumor volume analysis of neuroendocrine liver metastases by Gd-EOB MRI - A deep learning model to support multidisciplinary cancer conference decision making**

14:05 - 14:09  **Q & A**
Surgery and neoadjuvant therapy in NEN

**Time:** Thursday 14:45 - 15:45  
**Moderator:** Massimo Falconi, ITA / Eva Tiensuu Janson, SWE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:45 - 15:00</td>
<td><strong>Pan-NET and Si-NET - Current role of robotic-assisted resections</strong></td>
<td>Detlef Bartsch, GER</td>
</tr>
<tr>
<td>15:00 - 15:15</td>
<td><strong>Pan-NET and Si-NET - How to define locally borderline or not resectable?</strong></td>
<td>Marie-Pierre Vullierme, FRA</td>
</tr>
<tr>
<td>15:15 - 15:30</td>
<td><strong>Pan-NET and Si-NET - Is there a place for downsizing or neoadjuvant therapy in locally borderline or not resectable tumors?</strong></td>
<td>Stefano Partelli, ITA</td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td><strong>Is there a place for surgery in NEC G3?</strong></td>
<td>James Howe, USA</td>
</tr>
</tbody>
</table>

**BREAK**

**Time:** Thursday 15:45 - 16:00

**ENETS / European Society of Endocrinology (ESE)**

**Time:** Thursday 16:00 - 17:15  
**Moderator:** Simona Glasberg, ISR / Beata Kos-Kudła, POL

**Swinging between Hormones and NENs: Cutting-edge Developments**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 - 16:20</td>
<td><strong>Searching for MEN - Unmet clinical needs and challenges in genetic counselling</strong></td>
<td>Gerlof Valk, NED</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td><strong>MTC: Current challenges and unmet needs - New players on the stage</strong></td>
<td>Mimi I. Hu, USA</td>
</tr>
<tr>
<td>16:40 - 17:00</td>
<td><strong>Management of bone involvement in NENs - Whom, when, what, how much?</strong></td>
<td>Maria Luisa Brandi, ITA</td>
</tr>
<tr>
<td>17:00 - 17:15</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Closing comments**

**Time:** Thursday 17:15 - 17:30  
**Speaker:** Marianne Ellen Pavel, GER

**Satellite Symposium I - Industry-sponsored (Confirmed)**
**Time:** Thursday 17:30 - 19:00
**Friday, 26.02.2021**

**Welcome**

**Time:** Friday 10:45 - 10:55  
**Speaker:** Marianne Ellen Pavel, GER

**Plenary lecture**

**Time:** Friday 10:55 - 11:25  
**Moderator:** Dermot O’Toole, IRL

10:55 - 11:25  
**Radiomics in NEN**  
*Clarisse Dromain, SUI*

**Nuclear medicine diagnostic and therapy (PARALLEL SESSION)**

**Time:** Friday 11:25 - 12:45  
**Moderator:** Lisa Bodei, USA / Anders Sundin, SWE

---

**Functional imaging (11:25 - 12:05)**

11:25 - 11:45  
**FDG PET for all NET?**  
*Valentina Ambrosini, ITA / Andreas Kjaer, DEN*  
Debate: Affirmative speaker/Negative speaker

11:45 - 12:05  
**Functional imaging as a predictor of PRRT response: What is robust?**  
*Vikas Prasad, GER*

---

**New approaches to optimise treatments for PRRT (12:05 - 12:45)**

12:05 - 12:30  
**New tracers and combination and sequential therapies**  
*Damian Wild, SUI*

12:30 - 12:45  
**Discussion**

---

**ENETS Nurse & Dietitian Symposium (PARALLEL SESSION)**

**Time:** Friday 11:25 - 12:45  
**Chair:** Wanda Geilvoet, NED

11:25 - 11:30  
**Welcome & introduction**  
*Wanda Geilvoet, NED*

11:30 - 11:50  
**Need to know - A crash course in neuroendocrine tumor imaging**  
*Anders Sundin, SWE*

11:50 - 12:00  
**Research - Complementary and alternative medicine in NETs**  
*Mette Borre, DEN*

12:00 - 12:10  
**Reach out - How to reach the rare NET-nurses?**  
*Sophie Noble, GBR*

---

**Case studies (12:10 - 12:40)**

12:10 - 12:25  
**Insulinoma - A complex dilemma**  
*Deborah Pitfield, GBR*

12:25 - 12:40  
**Long term NET patient - Thinking outside the box**  
*Wendy Martin, GBR*
12:40 - 12:45  **Closing Comments**  
*Wanda Geilvoet, NED*

**BREAK**  
**Time:** Friday 12:45 - 13:30

**Recent results from clinical trials and key ongoing trials**  
**Time:** Friday 13:30 - 15:00  
**Moderator:** Rocio Garcia-Carbonero, ESP / John Ramage, GBR

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 13:50</td>
<td>Clinical trials design revisited - Future strategies and endpoints</td>
<td>Simron Singh, CAN</td>
</tr>
<tr>
<td>13:50 - 14:05</td>
<td>Clinical trials in Europe</td>
<td>Enrique Grande, ESP</td>
</tr>
<tr>
<td>14:05 - 14:20</td>
<td>Clinical trials in the Americas</td>
<td>Emily Bergsland, USA</td>
</tr>
<tr>
<td>14:20 - 14:35</td>
<td>Clinical trials in Asia and Australia</td>
<td>Jie Chen, CHN</td>
</tr>
<tr>
<td>14:35 - 15:00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**BREAK**  
**Time:** Friday 15:00 - 15:15

**Carcinoid heart disease**  
**Time:** Friday 15:15 - 16:15  
**Moderator:** Christos Toumpanakis, GBR / Jerome Zacks, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:15 - 15:25</td>
<td>Value of biomarkers for diagnosis and follow-up</td>
<td>Stephane Ederhy, FRA</td>
</tr>
<tr>
<td>15:25 - 15:35</td>
<td>Optimised therapeutic and perioperative management</td>
<td>Hans Hofland, NED</td>
</tr>
<tr>
<td>15:35 - 15:45</td>
<td>Percutaneous or surgical valve replacement - When is the right time?</td>
<td>Anders Albåge, SWE</td>
</tr>
<tr>
<td>15:45 - 15:55</td>
<td>Challenges in the clinical management of CHD</td>
<td>Simona Glasberg, ISR</td>
</tr>
<tr>
<td>15:55 - 16:15</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**Best abstracts: Translational research / Basic science (PARALLEL SESSION)**  
**Time:** Friday 16:15 - 17:30  
**Moderator:** Justo P. Castaño, ESP / Aurel Perren, SUI

<table>
<thead>
<tr>
<th>Time</th>
<th>Abstract</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>16:15 - 16:25</td>
<td>A patient derived organoid model of neuroendocrine neoplasms enables long term growth in vitro of low grade tumors and reveals therapeutic vulnerabilities</td>
<td></td>
</tr>
<tr>
<td>16:25 - 16:30</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>A molecular map of lung neuroendocrine neoplasms</td>
<td></td>
</tr>
</tbody>
</table>
16:40 - 16:45  Q & A
16:45 - 16:53  Immune heterogeneity and cascade of changes in subtypes of pancreatic neuroendocrine tumors
16:53 - 16:56  Q & A
16:56 - 17:04  Establishment of neuroendocrine neoplasms organoid biobank enables genotype-phenotype mapping
17:04 - 17:07  Q & A
17:07 - 17:15  Transcriptomic deconvolution of neuroendocrine neoplasms predicts clinically relevant characteristics
17:15 - 17:18  Q & A
17:18 - 17:26  Splicing machinery dysregulation in low grade pulmonary carcinoids
17:26 - 17:29  Q & A
17:29 - 17:30  Closing comments

INCA/ENETS Symposium - Patient impact on improving NET research and time to diagnosis (PARALLEL SESSION)

Time: Friday 16:15 - 17:30
Chairs: Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

16:15 - 16:20  Welcome and introductions from ENETS and INCA
Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

Part 1: Improving NET research (16:20 - 16:50)

16:20 - 16:23  Setting the scene: Why is patient-led/driven research instrumental?
Teodora Kolarova, BUL

16:23 - 16:50  Best practice examples of patient involvement in research

16:23 - 16:30  SCAN
Mark McDonnell, IRL

16:30 - 16:35  INCA boot camp for research advocates
Jackie Herman, CAN

16:35 - 16:40  Cell Line Project - Tumor tissue donation to facilitate research
Elyse Gellerman, USA

16:40 - 16:50  The value of patient-driven research
Jaume Capdevila, ESP

Part 2: Improving time to diagnosis (16:50 - 17:25)

16:50 - 16:58  Early diagnosis challenges as reported in SCAN & SCAN II launch
Sugandha Dureja, IND

16:58 - 17:05  Impact of misdiagnosis on healthcare systems and patients - Understanding the barriers to early diagnosis
Catherine Bouvier, GBR

17:05 - 17:10  Optimal care pathway for NETs
Simone Leyden, AUS
17:10 - 17:20  **NEN misdiagnosis and late diagnosis - How can we have a positive impact on changing the facts?**  
Dermot O'Toole, IRL

17:20 - 17:25  **Questions & answers**

17:25 - 17:30  **Take home messages and closing comments**  
Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

---

**Closing comments**

**Time:** Friday 17:30 - 17:45  
**Speaker:** Marianne Ellen Pavel, GER

**Satellite Symposium II - Industry-sponsored (Confirmed)**

**Time:** Friday 17:45 - 19:15
Saturday, 27.02.2021

Welcome
Time: Saturday 10:45 - 10:50
Speaker: Marianne Ellen Pavel, GER

Treatment outcomes
Time: Saturday 10:50 - 11:50
Moderator: Antongiulio Faggiano, ITA / Anja Rinke, GER

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 - 11:05</td>
<td>Psychological aspects - Basic conditions and impact of therapy in carcinoid syndrome</td>
<td>John Ramage, GBR</td>
</tr>
<tr>
<td>11:05 - 11:20</td>
<td>Treatment outcome in NEN patients based on gender</td>
<td>Pamela Kunz, USA</td>
</tr>
<tr>
<td>11:20 - 11:35</td>
<td>Treatment outcome in NEN patients with diabetes - Basic conditions and impact of therapy</td>
<td>Sara Pusceddu, ITA</td>
</tr>
<tr>
<td>11:35 - 11:50</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

Challenges and controversies (ENETS / NextGEN ENETS)
Time: Saturday 11:50 - 12:50
Moderator: Philippe Ruszniewski, FRA / Juan Valle, GBR

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:50 - 12:05</td>
<td>Where is the place for radiotherapy in the management of NEN?</td>
<td>David Chan, AUS</td>
</tr>
<tr>
<td>12:05 - 12:20</td>
<td>NET and pregnancy/fertility</td>
<td>Angela Lamarca, GBR</td>
</tr>
<tr>
<td>12:20 - 12:35</td>
<td>Intra-abdominal complications of NET (occlusion, peritoneal, carcinomatosis, fibrosis, ischemia) - How to prevent and how to treat?</td>
<td>Marc Peeters, BEL</td>
</tr>
<tr>
<td>12:35 - 12:50</td>
<td>Effects on investigations and therapy during COVID pandemic</td>
<td>Nicola Fazio, ITA</td>
</tr>
</tbody>
</table>

Satellite Symposium III - Industry-sponsored (Optional)
Time: Saturday 12:50 - 13:50

Pulmonary NET
Time: Saturday 13:50 - 15:05
Moderator: Eric Baudin, FRA

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:50 - 14:00</td>
<td>Limitations of the new WHO classification</td>
<td>Aurelie Fabre, IRL</td>
</tr>
<tr>
<td>14:00 - 14:10</td>
<td>Bronchial-NEN - What is the adequate extent of resection?</td>
<td>Pier Luigi Filosso, ITA</td>
</tr>
<tr>
<td>14:10 - 14:20</td>
<td>Who should receive adjuvant therapy or therapy for residual disease?</td>
<td>Debashis Sarker, GBR</td>
</tr>
<tr>
<td>14:20 - 14:35</td>
<td>Systemic therapy of lung carcinoids</td>
<td>Eric Baudin, FRA</td>
</tr>
</tbody>
</table>
14:35 - 14:45  
**Is there a place for immunotherapy in lung NEN?**  
*Jaume Capdevila, ESP*

14:45 - 15:05  
**Discussion**

---

**BREAK**

*Time*: Saturday 15:05 - 15:20

---

**What's new?**

*Time*: Saturday 15:20 - 16:20  
**Moderator**: *Eric Baudin, FRA / Elisabeth Nieveen van Dijkum, NED*

15:20 - 15:50  
**Translational NET update – Review of the year**  
*Justo P. Castaño, ESP*

15:50 - 16:20  
**ENETS abstracts highlights**  
*Nicholas Simon Reed, GBR*

---

**Awards Ceremony - Best abstracts 2021**

*Time*: Saturday 16:20 - 16:35  
**Moderator**: *Marianne Ellen Pavel, GER / Nicholas Simon Reed, GBR*

---

**Closing comments**

*Time*: Saturday 16:35 - 16:45

**Speaker**: *Marianne Ellen Pavel, GER*
European Neuroendocrine Tumor Society e.V. (ENETS)
Langenbeck-Virchow-Haus
Luisenstr. 58/59
10117 Berlin
VAT Nr.: DE252810143
Amtsgericht Charlottenburg: VR 23838 B
www.enets.org | info@enets.org